Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 6711 5081 6532 975--
Entreprise Value (EV)1 3681 5081 6532 4322 5882 777
P/E ratio -6,68x-12,5x-14,5x-23,3x-21,5x-15,4x
Yield ------
Capitalization / Revenue 109x63,1x10,1x15,4x15,6x20,1x
EV / Revenue 59,6x63,1x10,1x12,6x13,5x18,8x
EV / EBITDA ----17,1x-12,1x-10,9x
Price to Book ------
Nbr of stocks (in thousands) 62 73268 43175 04578 129--
Reference price (USD) 10,722,022,038,138,138,1
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 6,1823,9164193191148
EBITDA1 ----142-213-254
Operating profit (EBIT)1 -90,4-128-113-136-173-226
Operating Margin -1 463%-536%-68,9%-70,3%-90,7%-152%
Pre-Tax Profit (EBT)1 -88,9-120-113-125-163-214
Net income1 -88,9-120-113-127-149-205
Net margin -1 439%-504%-68,6%-65,6%-77,9%-138%
EPS2 -1,60-1,76-1,52-1,63-1,77-2,47
Dividend per Share2 ------
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
2 USD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 47,641,363,041,334,033,0
EBITDA ------
Operating profit (EBIT)1 -29,1-40,2-20,3-45,9-59,3-61,8
Operating Margin -61,1%-97,4%-32,2%-111%-174%-187%
Pre-Tax Profit (EBT)1 -30,0-40,3-16,3-38,8-55,0-58,5
Net income1 -30,0-40,8-17,1-38,8-55,0-58,5
Net margin -62,9%-98,7%-27,1%-94,0%-162%-177%
EPS2 -0,39-0,53-0,22-0,48-0,62-0,66
Dividend per Share ------
Announcement Date 05/06/202108/09/202111/09/2021---
1 USD in Million
2 USD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ------
Net Cash position1 303--544388198
Leverage (Debt / EBITDA) ---3,82x1,82x0,78x
Free Cash Flow 17,9-7,04163---
ROE (Net Profit / Equities) ----118%-393%-
Shareholders' equity1 ---10737,9-
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex1 0,366,3511,79,8013,313,2
Capex / Sales 5,81%26,6%7,15%5,08%6,96%8,92%
Announcement Date 03/11/201902/27/202002/25/2021---
1 USD in Million
Key data
Capitalization (USD) 2 975 166 714
Net sales (USD) 164 307 000
Number of employees 302
Sales / Employee (USD) 544 063
Free-Float 92,8%
Free-Float capitalization (USD) 2 761 971 113
Avg. Exchange 20 sessions (USD) 186 328 589
Average Daily Capital Traded 6,26%
EPS & Dividend